Vor Biopharma

About:

Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.

Website: https://www.vorbio.com

Top Investors: Alexandria Venture Investments, RA Capital Management, Fidelity, PureTech Health, OUP (Osage University Partners)

Description:

Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer. It is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells. Cell surface-targeted immunotherapies, such as bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor (CAR) T cells, generally target both cancer and normal cells, causing substantial toxicities and limiting their potential. The company is taking a fundamentally novel approach to targeting cancer selectively by developing hematopoietic stem cells (HSCs) that have been engineered to be protected from specifically targeted immunotherapies. These HSCs are designed to generate healthy, functional cells that are also protected from depletion by cancer-targeted therapies.

Total Funding Amount:

$268M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2016-01-01

Contact Email:

info(AT)vorbiopharma.com

Founders:

Aleks Radovic-Moreno, Siddhartha Mukherjee

Number of Employees:

101-250

Last Funding Date:

2022-12-07

IPO Status:

Public

Industries:

© 2025 bioDAO.ai